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Abstract: Evidence links dopamine release in the mid-brain to the pathophysiology of psychosis, addiction and reward. 
Repeated ingestion of refined carbohydrate may stimulate the same mesolimbic dopaminergic pathway, rewarding such 
eating behaviour and resulting in excessive food intake along with obesity. In this paper, we explore the role of dopamine 
in reward and psychosis, and discuss how reward pathways may contribute to the weight gain that commonly follows 
antipsychotic drug use, in people with psychotic illness. Our theory also explains the frequent co-occurrence of substance 
abuse and psychosis. From our hypothesis, we discuss the use of carbohydrate modified diets as an adjunctive treatment 
for people with psychosis. 
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BACKGROUND 
  The mesolimbic dopaminergic system of the mid brain is 
intimately linked to two major categories of disease (1) 
addiction, and (2) psychotic disorders. Although, the link 
between mental illness and addiction has been commonly 
reported [1], with increased prevalence of substance abuse in 
people with psychosis, the theoretical links between these 
disorders has not been explored in detail. In this article, we 
argue that psychosis and addiction are closely linked, sharing 
similar anatomical regions of the brain which demostrate 
dysfunction in both syndromes [1]. Because of such common 
features, we speculate that reducing the use of addictive 
substances in people with mental illness is likely to improve 
their underlying mental disorder. By achieving similar 
neurophysiological effects (less dopaminergic stimulation), 
reducing addiction is likely to complement the effect   
of antipsychotic drugs. Along with substance abuse,   
we argue that food intake shares clinical features of 
addiction; especially the consumption of sugars and refined 
carbohydrates. We first consider theoretical and observed 
links between psychosis and addiction, then postulate a   
new hypothesis, which may explain the weight gain that 
commonly occurs after antipsychotic drug use [2-5]. An 
important suggestion arising from this theory - that 
carbohydrate modified diets may improve the mental health 
of people who suffer from psychotic symptoms – is then 
outlined. 
  To explore the intersection of psychotic and addiction 
phenomena, first, we briefly define addiction, along with its 
clinical features. Next, we review the neuroanatomy and   
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physiology of the dopaminergic pathways in the midbrain, 
and how this region behaves in both disorders. We then 
discuss the mechanism of action of antipsychotic drugs and 
new evidence linking food intake and obesity with addiction. 
Our hypothesis then links psychosis, food and addiction and 
we explain how this may offer new dietary therapy for 
people with schizophrenia. 
ADDICTION 
  When does a person’s substance use cross the boundary 
to become an addiction? Controversy surrounds the 
definition, with different conceptions offered. Heather 
describes addiction as “repeated failures to refrain from 
drug use despite prior resolutions to do so” [6]. The DSM –
IV [7] criteria expand on this definition, requiring three or 
more of the following criteria occurring within a twelve 
month period: (1) taking larger amounts of the substance 
than intended; (2) unsuccessful efforts to cut down; (3) a 
great deal of time devoted to acquiring the substance; (4) 
giving up important activities because of substance use; (5) 
investing a great deal of time in acquiring or using the 
substance; (6) continued use despite negative consequences; 
(7) increased need for the substance indicating tolerance; and 
(8) withdrawal manifest by a characteristic syndrome if the 
substance is withdrawn or the substance is taken to avoid 
such discomfort. 
  The last feature of the DSM-IV criteria, the withdrawal 
syndrome, may be the most important, given the subjective 
nature of the other features. Withdrawal symptoms include 
depressed mood, disturbed sleep and a wide variety of 
somatic symptoms [8] and may often be subtle, described by 
recovering users as “just not feeling right”. Substance use 
relieves this discomfort, resulting in negative re-inforcement 
of the action with repeated drug use to avoid the unpleasant 
symptoms [9]. Opiate withdrawal, for example is characterised 
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intense craving, aches and pains, sweating and palpitations 
[10]. A contrasting cluster of symptoms is seen in tobacco 
withdrawal: notably craving and urges to smoke, irritability, 
reduced concentration, increased appetite and constipation 
[11]. Although the nature of these withdrawal states may be 
quite different, the time course over which the symptoms are 
experienced is roughly consistent, with the intensity peaking 
after three to four days, then gradually declining after one to 
three months of abstinence. 
PHYSIOLOGY OF ADDICTION 
  In the last thirty years the origin of clinical symptoms of 
addiction has been linked to a part of the brain responsible 
for subconscious behaviour and motivation, and a specific 
neurotransmitter: dopamine. The dopaminergic system is 
composed of two major pathways: (1) the nigrostriatal system 
that projects from the substantia nigra in the basal ganglia to 
the corpus striatum and (2) the mesocorticolimbic dopamine 
system, which emanates from the ventral tegmental area of 
the mid brain to the nucleus accumbens and olfactory 
tubercle (in the ventral striatum), medial pre-frontal cortex 
and amygdale (found in the temporal lobe) [12]. These 
neural pathways each have their own functions, which have 
been understood by their association with the symptom 
clusters that accompany disease states in their respective 
anatomical regions. The mesocorticolimbic projection is most 
often implicated in the pathophysiology of addiction and 
subconscious reward pathways. In human and animal studies, 
administration of substances of abuse increases dopamine 
concentrations in the nucleus accumbens, considered the 
main component of the brain reward system [12]. An 
intravenous bolus of cocaine, for example, causes increased 
extracellular concentrations of dopamine, blocking re-uptake 
by nerve terminals in the nucleus accumbens. In contrast, 
opioids, nicotine and alcohol act upstream, stimulating 
neurones in the ventral tegmental area, which ultimately 
influence the nucleus accumbens, by releasing dopamine at 
nerve terminals into the synaptic cleft and activating the 
nucleus. These three drugs either act directly on the cell 
bodies of these ventral tegmental neurones or block 
inhibition by GABA interneurones [13]. 
  Also, extracellular dopamine release in the striatum (from 
psychostimulants) and subjectively feeling “high” or 
euphoric [14] are closely linked, in human brain imaging 
studies. Although dopamine is often described as the 
“pleasure chemical”, this role is currently debated. Some 
suggest that dopamine release in the nucleus accumbens has 
less to do with reward, but is more likely to reinforce, 
strengthen and initiate movement required to attain the 
eventual reward, such as rolling a cigarette [15]. 
  The nigrostriatal pathway, which includes the substantia 
nigra, is best known for its relationship to the degenerative 
disorder, Parkinson’s disease, characterised by a cluster of 
motor and non-motor symptoms. Motor symptoms include a 
characteristic ‘pill-rolling’ tremor, shuffling gait, brady- 
kinesia (slowing of motor movements), and rigidity. Non-
motor manifestations consist of depressed mood, cognitive 
impairment along with autonomic and sleep disturbances. 
Replacement of dopamine, in precursor form (levodopa), 
partially relieves many of these symptoms. Degeneration of 
the dopaminergic neurones in this part of the brain are seen 
in post mortem studies of people who have died with 
Parkinson’s disease [16]. 
PATHWAYS OF ADDICTION TO FOOD 
  The mesolimbic dopaminergic pathway is activated by 
drugs and substances that people ingest, inject, snort or 
smoke that, ultimately, cross the blood brain barrier, after 
entry into the circulation. Over the last two decades, other 
evidence has implicated this pathway in weight control and 
eating behaviour. This evidence comes from a number of 
different studies. These include microdialysis, rodent based 
research of the mesolimbic pathway that have shown that 
exposure to food results in dopamine release. Although the 
quantity is less than what occurs in response to drugs of 
abuse, such as amphetamines [17]. The magnitude of 
dopamine release, in rodent models, is about 10 fold greater 
with a more rapid rate of initial rise, after an amphetamine 
bolus, compared to the release which follows a meal, mixed 
in macronutrients [18]. 
  It is also recognised that the brain’s primary fuel in the 
non-fasting state is glucose, and changes in venous glucose 
concentrations trigger changes in the firing of dopaminergic 
neurones in the striatum [19]. Other studies point to a direct 
physiological effect of plasma glucose on dopamine release 
in neuronal tissue. For example, Koshimura incubated nerve 
cells in high concentrations of glucose, and found that 
depolarisation and dopamine release was enhanced [20]. In 
addition, rodent studies have demonstrated that restricted 
feeding coupled with intermittent sucrose availability leads 
to up-regulation of the dopamine transporter in the nucleus 
accumbens and ventral tegmental area [21]. Sucrose 
consumption has also reliably induced signs of addiction in 
rodents, with demonstrated anxiety and somatic symptoms 
(withdrawal) following abstinence, or after naloxone (an 
opiate antagonist) administration [4]. Although high fat 
rodent diets also stimulate dopamine release in the nucleus 
accumbens, similar withdrawal symptoms were not observed 
when these animals were forced to abstain or treated with 
naloxone [22]. In humans, carbohydrate craving has often 
been reported, although a full withdrawal syndrome has   
not yet been described. We portrayed one individual who 
demonstrated a likely food withdrawal syndrome following 
abstinence from sugar and carbohydrate [23]. Another 
example is given by Atkins, in his well known book, 
portraying an obese individual who suffers from craving and 
agitation relieved by sugar, that eventually resolves within 
weeks after starting his carbohydrate restricting diet [24]. 
  Tolerance or need for an increased quantity of a 
substance to get the same ‘hit’ is a dominant feature of 
addiction and may reflect reduced sensitivity to dopamine by 
post-synaptic neurones in the nucleus accumbens. Anatomical 
changes found following Positron Emission Tomography 
studies of those who suffer from drug addiction show 
evidence of adaptation, with an increased concentration of 
dopamine receptors compared to controls [25]. Such changes 
in the accumbens also occur in obese individuals [26]. 
  Of all the food groups, carbohydrate is commonly 
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sugar or sucrose [28]. This disaccharide is composed of two 
chemically linked monosaccharides: glucose and fructose. 
Glucose is the primary energy source of the brain and other 
vital organs, compared to fructose which has stronger 
sensory qualities, percieved as about twice as sweet as 
similar concentrations of glucose. Fructose, unlike glucose, 
is taken up preferentially in the liver, and so, is almost absent 
in peripheral blood [29]. 
  The mechanism by which sucrose induces dopamine 
release is uncertain, however, two possibilities are 
commonly cited [30]. First, sugar may be ingested, absorbed 
and the glucose transported to the brain from the circulation, 
with subsequent dopamine release. Second, direct sensory 
input from taste and other sensory input in the mouth may 
provoke dopamine release. When rodents are “sham fed” – 
allowed to feed, but not digest food by having it pass out of 
the body via a gastric fistula - concentration-dependent 
dopamine release follows [30]. Further release of dopamine 
occurs during digestion and absorption of glucose, which is 
potentiated by glucose-mediated insulin release [31]. Such 
findings reiterate why fructose may be an important 
contributor to food addiction, owing to its sweeter taste. 
Importantly, fructose (unlike glucose) does not appear to 
stimulate insulin release, a hormone associated with post-
prandial satiety. 
  What are the clinical features of drug induced dopamine 
release in human subjects? Two principal effects are 
commonly described [13]. First, release is accompanied by 
pleasure, or the feeling of a ‘hit’ and behaviours that produce 
this are reinforced, forming a vicious cycle of increasing 
substance use. In addition, the increase in dopamine concentra-
tion focuses the individual on sensory elements (‘cues’) 
associated with drug taking. Such elements often initiates 
subconscious, Pavlovian stimulus-response drug taking when 
an individual is subsequently exposed to them again [13]. 
NEURAL PATHS ASSOCIATED WITH PSYCHOSIS 
  As well as playing a role in addiction, dopamine has been 
referred to as the “wind of the psychotic fire”, when 
describing its association with the pathophysiology of 
schizophrenia [32]. Evidence for dopamine's importance 
emerges from clinical practice - for example, treatment of 
patients with Parkinson’s disease using therapeutic doses of 
levo-dopa can result in a drug-induced psychosis in a small 
proportion of these patients [33]. Conversely, drugs used to 
treat psychoses such as schizophrenia inhibit dopaminergic 
pathways, and may result in unwanted Parkisonism. 
  Antipsychotic or ‘neuroleptic’ drugs have a specific 
mechanism of action. After entry into the circulation they 
diffuse across the blood-brain barrier. There, they bind to 
and block neural circuits, specifically interfering with the 
action of dopamine on mesolimbic and mesocortical D2
receptors [34]. Greater specificity for the blockade of 
serotonin receptor subtype 5-HT2A is a feature of atypical 
antipsychotic agents, such as clozapine and olanzapine. 
Although dopaminergic dysfunction is highlighted most 
frequently in the pathophysiology of psychosis, other neural 
paths are also implicated, such as the glutaminergic and 
serotonergic [35] ones. 
  Given the association between dopaminergic neural   
paths and addiction and psychosis, at a clinical level we may 
expect a close relationship between the two disorders. For 
example, in one summary, the prevalence of smoking was 
between 80 and 90% in people treated in hospital with 
schizophrenia [1]. Numerous epidemiological studies 
describe the co-occurrence of schizophrenia and other forms 
of addiction, such as to alcohol, metamphetamine and 
opiates. [1]. Further, the presence of illicit drug use in people 
with schizophrenia predicts relapse, treatment resistance and 
need for further hospital treatment [1]. 
  Researchers have concluded that no drug with significant 
antipsychotic action has been identified that does not have a 
significant affinity for the D2 receptor [36]. In the spinal 
fluid of psychotic patients, maintained on a variety of 11 
different antipsychotic drugs, seventy percent blockade of 
the D2 receptor in vitro correlated to therapeutic free 
neuroleptic levels [36]. The altered side effect profiles 
attributable to newer antipsychotic agents have been linked 
to their briefer occupancy of the D2 receptor site (in contrast 
to older agents, which bind for longer) along with increased 
serotonergic effects. 
  For a long time, activity in the dopaminergic system has 
been difficult to directly assess in human subjects, but 
recently, positron and photon emission tomographic 
techniques have enabled this pathway to be studied in detail. 
Several connections between dopamine and psychosis are 
described. First, amphetamine induced dopamine release is 
exaggerated in people with schizophrenia; second, after 
amphetamine administration, dopamine release is associated 
with psychotic symptoms; and third, these changes in 
dopaminergic physiology in people with schizophrenia have 
been detected in patients never treated with antipsychotic 
drugs [32]. This last finding indicates that such phenomena 
are unlikely to represent neuroadaptation to antipsychotic 
medication. 
  What is the consequence of excess ‘reward’ or   
‘re-inforcement’ from dopamine release? Recent theories 
suggest that in people with schizophrenia, dopamine release 
leads to aberrant salience or focussing on innocuous stimuli 
[37]. Symptoms of hallucinations and psychosis emerge, 
resulting from a patient’s attempt to explain the increased 
attention they give to such stimuli. This mechanism may also 
explain the negative symptoms of schizophrenia, such as 
social withdrawal and lack of motivation. The increased 
“noise” in the reward pathway, due to aberrant dopamine 
release, may drown out the normal linkage and learning that 
accompanies behaviours that lead to reward from dopamine 
release [37]. 
HYPOTHESIS 
  If dopamine is the principal neurotransmitter mediating 
both re-enforcing behaviour and reward from ingestion of 
food, what are the likely consequences of blocking this 
action with antipsychotic drugs? Our hypothesis links the 
increased prevalence of obesity found in people treated with 
anti-psychotic agents and the known pharmacodynamic 
properties of such drugs - blocking dopamine effects in   
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compensate for the reduced reward after taking neuroleptics, 
patients exaggerate the stimulation of this pathway by 
increasing their food intake, or use of other addictive 
substances. 
SUPPORT FOR THIS HYPOTHESIS 
  Rodent studies have supported our hypothesis that 
antipsychotic drug use enhances feeding behaviour. In 
general, long term exposure of rodents to antipsychotic 
agents is associated with weight gain [4], although some 
short term studies show inconsistent results. The most 
conclusive study showed both a dose response effect 
(increased weight gain with increased dose), and reversal of 
this effect with bromocriptine, a specific dopamine (D2)
receptor agonist [4]. Four antipsychotic drugs consistently 
produced weight gain (thioridazine, trifluoperazine, halop-
eridol, and sulpiride), whilst chlorpromazine and fluphenazine 
did not. Another study documented increased food consump- 
tion in rodents treated with olanzapine, an atypical anti- 
psychotic medication, compared to untreated controls   
[38]. 
  In human subjects, weight gain commonly occurs in 
association with antipsychotic use, however the mechanism 
underlying this effect is not well understood. Several 
explanations are proposed, including increased appetite, 
leading to excess energy intake [3]. Metabolic changes, 
which lead to reduced metabolic rate, such as insulin 
resistance, have also been described [3, 39]. For example, 
weight gain has been consistently reported with clozapine – a 
retrospective study of 82 patients, followed up to 90 months, 
showed a cumulative incidence of a 10% weight gain in 80% 
of subjects, with a 20% weight gain observed in 38% [40]. 
Many other studies have confirmed such findings and some 
authors link weight gain with clinical improvement in mental 
state [41, 42]. The mechanism underlying these changes in 
weight has remained uncertain, with a number of neurotrans- 
mitters and hormones implicated [2] within serotonergic, 
histaminergic and adrenergic pathways [3]. 
  We speculate that if dopaminergic neural transmission is 
blocked by antipsychotic drugs in patients with schizophrenia, 
compensation may occur, with patients adapting by carrying 
out behaviours that stimulate dopamine release (from food or 
drug intake) in an effort to maintain homeostasis, achieving 
the same feeling of reward, satisfying hunger or drug 
withdrawal symptoms. Evidence for such an effect can be 
found in animal experiments which demonstrate dulling 
effects of antipsychotic drugs on chemical or electrical 
stimulation of mid- brain reward paths [17]. Also, animal 
studies of amphetamine and cocaine self administration   
show that short term compensatory increases occur after 
neuroleptic treatment [43]. An older study showed that the 
rewarding qualities of food were blocked by neuroleptics in 
hungry rats [44]. Although many recreational drugs induce 
dopamine release, the ubiquity of carbohydrate containing 
food may make this the most common means of 
compensating for the action of antipsychotic drugs. People 
with schizophrenia often, however, may use other drugs to 
compensate for dopamine blockade, and indeed substance 
(cocaine, cigarette, alcohol, methamphetamine) abuse and 
psychosis commonly coexist. 
  Our theory focuses on the centrality of the dopamine 
receptor blockade of antipsychotic drugs and their 
simultaneous effects on weight gain and psychosis. One 
potential flaw in this theory is the differential effects on 
weight gain of different drugs. For example, in studies   
in which patients are followed for less than one year   
of treatment, a clear hierarchy of weight gain liability   
occurs, with clozapine>olanzapine>risperidone>ziprasidone= 
aripiprazole [5]. Although all of these drugs block D2 receptors, 
they vary substantially in the amount of serotonergic, 
histaminergic and adrenergic activity they exhibit. Such a 
finding may indicate that other pathways or neurotransmitters 
are more likely to be causally implicated in weight gain side 
effects than the dopaminergic path. However, in studies 
which observe weight gain in patients treated for more than 
one year, such differences between drugs are less marked, 
and some of the between drug heterogeneity may be 
explained by between-study variation in dosing [45]. 
IMPLICATIONS 
  How might our theory improve care for people with 
psychosis? We speculate that if addiction and psychosis 
share common features and a common neuroanatomical 
pathway, with dopamine release and disordered reward and 
motivation, a key treatment for reducing the severity of 
psychosis may involve reducing stimulation of the mid brain. 
If antipsychotic drugs exert their effect, principally, by 
blocking the effects of mesolimbic dopamine release, we 
expect that reduced release of dopamine in this pathway may 
result in similar beneficial effects on psychotic symptoms in 
people affected by schizophrenia. Although still contro- 
versial, we speculate that food may be a key stimulant of this 
disordered pathway, and altering diet may improve psychosis 
and reduce the need for antipsychotic treatment. If blocking 
the effects of free dopamine reduces psychotic symptoms, 
then reducing dopamine release is likely to induce a similar 
effect. Offering treatment for other addictions (not only 
food) to limit dopamine release also follows from our theory. 
  Surprisingly, evidence for nutrition interventions to 
improve psychotic symptoms has received little attention. 
Peet speculated that the co-occurrence of schizophrenia   
and diabetes, even in drug naive patients, suggests that the 
two disorders share a common aetiology [46]. One study 
reports high levels of sugar consumption in patients with 
schizophrenia, although the authors are uncertain whether 
this is a cause or consequence of treatment for the disease 
[47]. Dietary treatment for patients with schizophrenia 
usually consists of reducing long term cardiovascular and 
diabetes risk, rather than being viewed as an integral part of 
reducing psychotic symptoms. To our knowledge, the effect 
on psychopathology of reducing sugar or carbohydrate 
consumption among a cohort of people with schizophrenia 
has not been studied. 
  If a dietary approach to treating psychotic symptoms was 
suggested, what might this regime look like? Glycemic index 
(GI) describes the rate of absorption of glucose from carbo-
hydrate. High GI carbohydrate foods, such as white bread, 
sugar and refined cereals, cause a ‘spike’ in insulin and 
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foods, such as wholegrain bread and most vegetables (or 
foods containing little carbohydrate at all, such as nuts, seeds 
and meat), produce a slower insulin response and thus a 
more steady supply of glucose to the blood. Low GI diets 
induce weight loss and improve blood glucose control in 
people with diabetes. A recent meta-analysis showed that 
people following a low GI diet had more weight loss than 
other diets [48]. Other meta-analyses indicate a lower risk of 
chronic diseases such as cancer and cardiovascular disease 
occur in people following low GI diets [49]. We speculated 
that one indicator of the addictive potential of food is the 
glycaemic index, based on the principle that ‘time-to-reward’ 
(or in pharmacokinetic terms, rate of rise of plasma concen-
tration) predicts the addictive potential of a substance [50]. 
Although this scale discounts the importance of sugar 
content, due to the presence of fructose which has little effect 
on blood glucose. The two best known diets based on 
modifying carbohydrate consumption include the glycaemic 
index and the Atkins diet. Low GI diets emphasise the 
selection of foods with a low to moderate index (<55%) [51]. 
The Atkins diet is more strict, with very low carbohydrate 
consumption (<20g/day) in the initial phases, with a 
graduated re-introduction of this food group after initial 
weight loss [24]. Studies of the effects of low glycaemic 
index diets on dopamine release are yet to be carried out, 
however anecdotal reports suggest an initial discomfort   
and craving after starting this regime, which suggests a 
component of withdrawal. 
  Studies that measure the effect of carbohydrate modified 
diets on psychotic symptoms would test whether our 
hypothesis is tenable. Drop out and compliance with 
carbohydrate restricted or modified diets is often low, and 
engagement of people with schizophrenia in such treatment 
may be more complicated than those which involve obese 
people. Nevertheless, a non-pharmacological approach to the 
treatment of psychosis may be more acceptable than drug 
treatments that are often associated with unpleasant side 
effects and low levels of adherence to treatment. Carbohydrate 
modified diets may also provide an adjunct to antipsychotic 
medication, potentially limiting unintended effects such as 
weight gain and adverse increases of other indices of 
cardiovascular risk. Meta-analyses of low glycaemic index 
diets show that these interventions are effective for achieving 
sustained weight loss in obese people [31] and reducing the 
risk of a range of chronic diseases such as such as type 2 
diabetes, coronary heart disease, gallbladder disease, breast 
cancer and all diseases combined (Rate Ratio 1.14, 95% CI 
1.04 to 1.15) [52]. Given the increased mortality associated 
with schizophrenia [53-55], use of these diets among people 
with psychotic illness may achieve a reduction in the   
inequity of physical health status and longevity compared 
with people without such conditions. 
  Our hypothesis also reinforces the rationale for treat- 
ment of addictions in people with schizophrenia. The use   
of short-term nicotine replacement therapy and quit   
advice, limitation of caffeine intake, and treatment of 
methamphetamine, alcohol and other substance abuse in 
such patients are likely to not only improve the patient’s 
general health, but also assist their recovery from psychosis. 
CONCLUSION 
  Our theory provides a parsimonious and testable 
hypothesis, linking the action of antipsychotic agents with 
commonly reported side effects. It also explains the common 
co-occurrence of schizophrenia with addiction, obesity and 
diabetes. The common link drawn between eating, psychosis 
and mid-brain dopaminergic reward, logically, suggests that 
psychosis may be improved, by modifying carbohydrate 
consumption. We consider that such an idea should be tested 
in clinical trials. 
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